112 related articles for article (PubMed ID: 16777626)
1. [New generation cytokines to prevent anemia and febrile neutropenia].
Fayette J; Blay JY
Bull Cancer; 2006 May; 93(5):483-7. PubMed ID: 16777626
[TBL] [Abstract][Full Text] [Related]
2. Managing hematologic toxicities: novel therapies.
Nirenberg A
Cancer Nurs; 2003 Dec; 26(6 Suppl):32S-37S. PubMed ID: 15025411
[TBL] [Abstract][Full Text] [Related]
3. The benefits of haematopoietic growth factors in the management of gynaecological oncology.
Dale DC
Eur J Gynaecol Oncol; 2004; 25(2):133-44. PubMed ID: 15032269
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.
Burstein HJ; Parker LM; Keshaviah A; Doherty J; Partridge AH; Schapira L; Ryan PD; Younger J; Harris LN; Moy B; Come SE; Schumer ST; Bunnell CA; Haldoupis M; Gelman R; Winer EP
J Clin Oncol; 2005 Nov; 23(33):8340-7. PubMed ID: 16293865
[TBL] [Abstract][Full Text] [Related]
5. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment.
Younossi ZM; Nader FH; Bai C; Sjogren R; Ong JP; Collantes R; Sjogren M; Farmer D; Ramsey L; Terra K; Gujral H; Gurung C; Srishord M; Fang Y
J Viral Hepat; 2008 May; 15(5):370-8. PubMed ID: 18194172
[TBL] [Abstract][Full Text] [Related]
6. Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
Miller AA; Wang XF; Gu L; Hoffman P; Khatri J; Dunphy F; Edelman MJ; Bolger M; Vokes EE; Green MR;
J Thorac Oncol; 2008 Oct; 3(10):1159-65. PubMed ID: 18827613
[TBL] [Abstract][Full Text] [Related]
7. A prospective randomised evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia.
Lalami Y; Paesmans M; Aoun M; Munoz-Bermeo R; Reuss K; Cherifi S; Alexopoulos CG; Klastersky J
Support Care Cancer; 2004 Oct; 12(10):725-30. PubMed ID: 15235901
[TBL] [Abstract][Full Text] [Related]
8. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany].
Sehouli J; Goertz A; Steinle T; Dubois R; Plesnila-Frank C; Lalla A; von Minckwitz G
Dtsch Med Wochenschr; 2010 Mar; 135(9):385-9. PubMed ID: 20180162
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-associated hematopoietic toxicity.
Kuhn JG
Am J Health Syst Pharm; 2002 Aug; 59(15 Suppl 4):S4-7. PubMed ID: 12166034
[TBL] [Abstract][Full Text] [Related]
10. Comment: Epoetin alfa versus darbepoetin alfa for cancer patients with treatment-related anemia.
Yang MC
Ann Pharmacother; 2006 May; 40(5):998-9; author reply 999. PubMed ID: 16670351
[No Abstract] [Full Text] [Related]
11. Epoetin alfa and darbepoetin alfa go head to head.
Steensma DP; Loprinzi CL
J Clin Oncol; 2006 May; 24(15):2233-6. PubMed ID: 16710021
[No Abstract] [Full Text] [Related]
12. Treatment of anemia in myelodysplastic syndrome with darbepoetin and granulocyte colony stimulating factor.
Rose S; Ali Y; Maffei B; Saidi P
Am J Hematol; 2007 Mar; 82(3):245-6. PubMed ID: 16924646
[No Abstract] [Full Text] [Related]
13. Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.
Ricotta R; Cerea G; Schiavetto I; Maugeri MR; Pedrazzoli P; Siena S
Future Oncol; 2006 Dec; 2(6):667-76. PubMed ID: 17155894
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer.
Riikonen P; Rahiala J; Salonvaara M; Perkkiö M
Stem Cells; 1995 May; 13(3):289-94. PubMed ID: 7542114
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
Case AS; Rocconi RP; Kilgore LC; Barnes MN
Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
[TBL] [Abstract][Full Text] [Related]
16. Filgrastim in patients with neutropenia: potential effects on quality of life.
Lyman GH; Kuderer NM
Drugs; 2002; 62 Suppl 1():65-78. PubMed ID: 12479595
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
Lathia N; Isogai PK; De Angelis C; Smith TJ; Cheung M; Mittmann N; Hoch JS; Walker S
J Natl Cancer Inst; 2013 Aug; 105(15):1078-85. PubMed ID: 23873405
[TBL] [Abstract][Full Text] [Related]
18. The development of supportive-care agents for patients with cancer.
Neumann TK; Foote M
Biotechnol Annu Rev; 2003; 9():397-417. PubMed ID: 14650936
[TBL] [Abstract][Full Text] [Related]
19. [G-CSF in oncology].
Viret F; Gonçalves A; Tarpin C; Chabannon C; Viens P
Bull Cancer; 2006 May; 93(5):463-71. PubMed ID: 16777624
[TBL] [Abstract][Full Text] [Related]
20. Darbepoetin alpha coming of age.
Pedrazzoli P; Cinieri S; Lorusso V; Gamucci T; Secondino S; Silvestris N
Anticancer Res; 2007; 27(6C):4419-24. PubMed ID: 18214054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]